Basalog® is similar to Lantus® in producing glycemic control in patients with type 1 diabetes mellitus on multiple daily insulin regimens

International Journal of Diabetes in Developing Countries

Volumn 31, Issue 1, 2011, Pages 26-31

  Verma, M ^a   Hazra, P ^a   Iyer, H ^a   Arun, A ^a   Akundi, S ^a   Dixit, M N ^a   Eswaraiah, A ^b   Prasanna, C G ^b   Atignal, A ^b  

^a Biocon Limited   (India)

^b Clinigene International Limited   (India)

Author keywords

Basal insulin; Glargine; Type 1 diabetes

Indexed keywords

EID: 79954433316     PISSN: 09733930     EISSN: 19983832     Source Type: Journal    
DOI: 10.1007/s13410-010-0010-2     Document Type: Article

References (8)

1. S Wild G Roglic A Green R Sicree H King 2004 Global prevalence of diabetes: estimates for the year 2000 and projections for 2030 Diabetes Care 27 5 1047 53 15111519 10.2337/diacare.27.5.1047 (Pubitemid 38579764)
2. DM Nathan JB Buse MB Davidson E Ferrannini RR Holman R Sherwin, et al. 2009 Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes Diabetes Care 32 1 193 203 18945920 10.2337/dc08-9025 1:CAS:528:DC%2BD1MXhs1Gns78%3D
3. US Prescribing Information of Lantus. Sanofi-aventis U.S. LLC; 2007.
4. P Raskin L Klaff R Bergenstal JP Halle D Donley T Mecca 2000 A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes Diabetes Care 23 11 1666 71 11092290 10.2337/diacare.23.11.1666 1:CAS:528:DC%2BD3cXot1ahs7k%3D
5. RE Ratner IB Hirsch JL Neifing SK Garg TE Mecca CA Wilson 2000 Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes Diabetes Care 23 5 639 43 10834423 10.2337/diacare.23.5.639 1:CAS:528:DC%2BD3cXnvVymsLY%3D (Pubitemid 30321544)
6. K McKeage KL Goa 2001 Insulin glargine: a review of its therapeutic use as a long-acting agent for the management of type 1 and 2 diabetes mellitus Drugs 61 11 1599 624 11577797 10.2165/00003495-200161110-00007 1:CAS:528:DC%2BD3MXnvVCqs7w%3D (Pubitemid 32905280)
7. H Yki-Jarvinen A Dressler M Ziemen 2000 Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group Diabetes Care 23 8 1130 6 10937510 10.2337/diacare.23.8. 1130 1:CAS:528:DC%2BD3cXnvV2js7g%3D (Pubitemid 30616801)
8. J Rosenstock SL Schwartz CM Clark Jr GD Park DW Donley MB Edwards 2001 Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin Diabetes Care 24 4 631 6 11315821 10.2337/diacare.24.4.631 1:CAS:528:DC%2BD3MXivVOmtbg%3D (Pubitemid 32888839)